TRANSCATHETER AORTIC VALVE IMPLANTATION MARKET ANALYSIS

Regional Analysis

Europe holds a dominant position in the global transcatheter aortic valve implantation market

On the basis of geography, the global transcatheter aortic valve implantation market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. Europe holds the maximum share of the global transcatheter aortic valve implantation market, attributing to the high prevalence of aortic stenosis in the European countries. The transcatheter aortic valve implantation is a well- established procedure offering reimbursement in most of the European countries and have specific procedure codes for TAVI, except for Italy. North America is also focusing on expansion of the TAVI market by investing in R&D for innovative transcatheter aortic valve implants. For instance, the U.S. FDA approved an expanded indication for the Sapien 3 transcatheter heart valve in June 2017. Asia Pacific is also expected to exhibit increased market growth over the recent future, owing to the introduction of novel and innovative products for the treatment of aortic stenosis. For example, the Food and Drug Administration of China recently approved a new generation valve replacement product called as J-Valve, which is expected to greatly reduce the surgical time as well as increase the rate of survival for most patients.

Geographies covered: North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.